Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640249 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3006072 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01640249 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01640249, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. The study drug will be given in the morning or evening with or without a meal. This is the first time that this study drug is being given to humans. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG LY3006072
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-07-24 |
| Est. Completion | 2012-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640249
The ClinicalTrials.gov registry entry for NCT01640249 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01640249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01640249 about?
NCT01640249 is a clinical study titled "A Study of LY3006072 in Healthy Participants". The purpose of this study is to evaluate how safe LY3006072 (study drug) is and whether it causes any side effects. The study will also measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of the study drug. The study drug will be given in the morni...
What is the current status of trial NCT01640249?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-07-24. Estimated completion is 2012-11-26.
What interventions are being tested in trial NCT01640249?
The interventions under investigation include: Placebo (DRUG), LY3006072 (DRUG).
Who is sponsoring clinical trial NCT01640249?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.